Urgent need to accelerate UK childhood cancer diagnosis
Childhood cancer affects 400,000 children globally each year. Prompt diagnosis of childhood cancer is crucial for optimising survival and outcomes.…
All articles by GlobalData Healthcare
GlobalData Healthcare
-
-
ASCO 2025: Johnson & Johnson’s Akeega set to be first PARP therapy for mCSPC
At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 31 May to 3 June in Chicago,…
-
ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers
Small cell lung cancer (SCLC) accounts for 10-15% of all lung cancer cases annually, with 250,000 incident cases diagnosed every…
-
ASCO 2025: GSK’s Jemperli fails to show OS benefit in 1L advanced ovarian cancer
At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 31 May to 3 June in Chicago,…
-
ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer
Corcept Therapeutics’ relacorilant, a selective glucocorticoid receptor antagonist (SGRA), is emerging as a novel therapeutic candidate in the treatment of…
-
ASCO25: Focus V fails to show superiority over bevacizumab in first-line metastatic CRC
At the American Society of Clinical Oncology (ASCO) Annual Meeting, being held 31 May - 3 June, results from the…
-
ASCO25: Trodelvy and Keytruda to become new standard of care for frontline TNBC
At the American Society of Clinical Oncology (ASCO) Annual Meeting, held 30 May-3 June 2025, primary results were presented from…
-
PureTech’s LYT-100 may expand treatment options for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterised by scarring of lung tissue, leading to impaired lung…
-
ASCO25: AstraZeneca’s novel trial design for camizestrant pays off in breast cancer
AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 conference, held in…
-
Sibeprenlimab’s priority review highlights potential to differentiate in IgAN space
Otsuka Pharmaceuticals recently announced that the FDA has accepted for review the biologics licence application (BLA) for sibeprenlimab. Sibeprenlimab acts…